Genetronics, Inc.On October 6, 1998 Genetronics entered into comprehensive development and license agreements involving its proprietary drug delivery system for Electroporation Therapy treatment of cancer with Ethicon, Inc., a Johnson & Johnson company

Essential Therapeutics, Inc. Cephalosporin which is currently in pre-clinical stages - and will target Staphylococcal infections, Enterococcal infections, and Streptococcus pneumoniae infections.